If you have been reading about Semax and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥ 95 % of peak area by HPLC | Some suppliers quote 98 % or higher |
| Identity confirmation | Mass spectrometry (electrospray or MALDI) | Observed mass is compared with the calculated mass |
| Common analytical method | Reversed-phase HPLC on a C18 column | Acetonitrile and water gradients with trifluoroacetic acid |
| Primary degradation route | Oxidation of the methionine residue | Yields a sulfoxide that separates cleanly on chromatography |
| Storage of dissolved material | Aliquoted and frozen at −20 °C or below | Single-use aliquots avoid repeated temperature cycling |
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
== Registration == The U.S. Centers for Disease Control and Prevention administers a regulatory framework for disinfectants and sterilants. To earn virucidal registration, extensive data on harder-to-kill viruses demonstrating long-lasting virucidal efficacy need to be provided.
About 20,000 protein-coding genes are expressed in human cells: 70% of these genes are expressed in thyroid cells. Two-hundred and fifty of these genes are more specifically expressed in the thyroid, and about 20 genes are highly thyroid specific. In the follicular cells, the proteins synthesized by these genes direct thyroid hormone synthesis—thyroglobulin, TPO, and IYD; while in the parafollicular c-cells, they direct calcitonin synthesis—CALCA, and CALCB.
The free cysteine nucleophile forms a bond with the phosphorus atom of the phosphate moiety, and the P-O bond linking the phosphate group to the tyrosine is protonated, either by a suitably positioned acidic amino acid residue (Asp in the diagram below) or a water molecule. The phospho-cysteine intermediate is then hydrolysed by another water molecule, thus regenerating the active site for another dephosphorylation reaction. Metallo-phosphatases (e.g. PP2C) co-ordinate 2 catalytically essential metal ions within their active site. There is currently some confusion of the identity of these metal ions, as successive attempts to identify them yield different answers. There is currently evidence that these metals could be magnesium, manganese, iron, zinc, or any combination thereof. It is thought that a hydroxyl ion bridging the two metal ions takes part in nucleophilic attack on the phosphorus ion.
Sources: en.wikipedia.org
== Description == There is no mention of the Korean People's Revolutionary Army in documents written by Kim Il Sung himself during his time in the Soviet Army. Coined in the wake of the May 25th Instructions, the purported army is connected to Kim Il Sung's cult of personality initiated by the guerrilla faction from the Soviet Army's 88th Separate Rifle Brigade, which seized power in North Korea. The KPRA was first mentioned in the late 1940s. Korean People's Revolutionary Army was allegedly founded on 25 April 1932. North Korean historiography credits the defeat of Japan in 1945 mostly to the KPRA, downplaying Soviet involvement. From 1978, North Korea marked 25 April as the "true" founding date of the Korean People's Army (KPA), with the KPA being claimed to just be the reconstitution of the KPRA. North Korean leader Kim Jong Un moved back the KPA's official founding date back to its original date of 8 February 1948, with 25 April instead becoming the official foundation date of the KPRA
=== Taste === Salts can elicit all five basic tastes, e.g., salty (sodium chloride), sweet (lead diacetate, which will cause lead poisoning if ingested), sour (potassium bitartrate), bitter (magnesium sulfate), and umami or savory (monosodium glutamate).
Bonded leather is made by shredding leather scraps and leather fiber, then mixing it with bonding materials. The mixture is next extruded onto a cloth or paper backing, and the surface is usually embossed with a leather-like texture or grain. Color and patterning, if any, are a surface treatment that does not penetrate like a dyeing process would. The natural leather fiber content of bonded leather varies. The manufacturing process is somewhat similar to the production of paper. Lower-quality materials may suffer flaking of the surface material in as little as a few years, while better varieties are considered very durable and retain their pattern and color even during commercial use. Because the composition of bonded leathers and related products varies considerably, and is sometimes a trade secret, it may be difficult to predict how a given product will perform over the course of time. There is a wide range in the longevity of bonded leathers and related products; some better-quality bonded leathers are claimed to be superior in durability over low-quality genuine leather.
==== MeSH D12.776.624.664.700 – proto-oncogene proteins ==== MeSH D12.776.624.664.700.100 – cyclin d1 MeSH D12.776.624.664.700.110 – fibroblast growth factor 4 MeSH D12.776.624.664.700.112 – fibroblast growth factor 6 MeSH D12.776.624.664.700.114 – fms-like tyrosine kinase 3 MeSH D12.776.624.664.700.120 – receptor, fibroblast growth factor, type 3 MeSH D12.776.624.664.700.130 – muts homolog 2 protein MeSH D12.776.624.664.700.148 – myeloid-lymphoid leukemia protein MeSH D12.776.624.664.700.167 – proto-oncogene proteins c-abl MeSH D12.776.624.664.700.168 – proto-oncogene proteins c-akt MeSH D12.776.624.664.700.169 – proto-oncogene proteins c-bcl-2 MeSH D12.776.624.664.700.170 – proto-oncogene proteins c-bcl-6 MeSH D12.776.624.664.700.171 – proto-oncogene proteins c-bcr MeSH D12.776.624.664.700.172 – proto-oncogene proteins c-cbl MeSH D12.776.624.664.700.174 – proto-oncogene proteins c-crk MeSH D12.776.624.664.700.175 – proto-oncogene proteins c-ets MeSH D12.776.624.664.700.175.100 – proto-oncogene protein c-ets-1 MeSH D12.776.624.664.700.175.200 – proto-oncogene protein c-ets-2 MeSH D12.776.624.664.700.175.400 – proto-oncogene protein c-fli-1 MeSH D12.776.624.664.700.175.600 – ternary complex factors MeSH D12.776.624.664.700.175.600.100 – ets-domain protein elk-1 MeSH D12.776.624.664.700.175.600.300 – ets-domain protein elk-4 MeSH D12.776.624.664.700.177 – proto-oncogene proteins c-fes MeSH D12.776.624.664.700.179 – proto-oncogene proteins c-fos MeSH D12.776.624.664.700.180 – proto-oncogene proteins c-fyn MeSH D12.776.624.664.700.181 – proto-oncogene proteins c-hck MeSH D12.776.624.664.700.182 – proto-oncogene proteins c-jun MeSH D12.776.624.664.700.183 – proto-oncogene proteins c-kit MeSH D12.776.624.664.700.184 – proto-oncogene proteins c-maf MeSH D12.776.624.664.700.185 – proto-oncogene proteins c-mdm2 MeSH D12.776.624.664.700.186 – proto-oncogene proteins c-met MeSH D12.776.624.664.700.187 – proto-oncogene proteins c-mos MeSH D12.776.624.664.700.188 – proto-oncogene proteins c-myb MeSH D12.776.624.664.700.189 – proto-oncogene proteins c-myc MeSH D12.776.624.664.700.191 – proto-oncogene proteins c-pim-1 MeSH D12.776.624.664.700.192 – proto-oncogene proteins c-rel MeSH D12.776.624.664.700.194 – proto-oncogene proteins c-ret MeSH D12.776.624.664.700.195 – proto-oncogene proteins c-sis MeSH D12.776.624.664.700.198 – proto-oncogene proteins c-vav MeSH D12.776.624.664.700.199 – proto-oncogene proteins c-yes MeSH D12.776.624.664.700.200 – proto-oncogene proteins p21(ras) MeSH D12.776.624.664.700.202 – proto-oncogene proteins pp60(c-src) MeSH D12.776.624.664.700.204 – raf kinases MeSH D12.776.624.664.700.204.200 – proto-oncogene proteins b-raf MeSH D12.776.624.664.700.204.500 – proto-oncogene proteins c-raf MeSH D12.776.624.664.700.205 – RNA-binding protein EWS MeSH D12.776.624.664.700.250 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D12.776.624.664.700.642 – receptor, erbb-2 MeSH D12.776.624.664.700.790 – receptor, erbb-3 MeSH D12.776.624.664.700.800 – receptor, macrophage colony-stimulating factor MeSH D12.776.624.664.700.830 – receptors, thyroid hormone MeSH D12.776.624.664.700.830.500 – thyroid hormone receptors alpha MeSH D12.776.624.664.700.830.750 – thyroid hormone receptors beta MeSH D12.776.624.664.700.915 – RNA-binding protein FUS MeSH D12.776.624.664.700.957 – stathmin MeSH D12.776.624.664.700.967 – wnt1 protein MeSH D12.776.624.664.700.978 – wnt2 protein
Sources: en.wikipedia.org
=== Mass spectrometry === Biochemical approaches such as Western blotting may provide supporting evidence that a protein is modified by O-GlcNAc; mass spectrometry (MS) is able to provide definitive evidence as to the presence of O-GlcNAc. Glycoproteomic studies applying MS have contributed to the identification of proteins modified by O-GlcNAc. As O-GlcNAc is substoichiometric and ion suppression occurs in the presence of unmodified peptides, an enrichment step is usually performed prior to mass spectrometry analysis. This may be accomplished using lectins, antibodies, or chemical tagging. The O-GlcNAc modification is labile under collision-induced fragmentation methods such as collision-induced dissociation (CID) and higher-energy collisional dissociation (HCD), so these methods in isolation are not readily applicable for O-GlcNAc site mapping. HCD generates fragment ions characteristic of N-acetylhexosamines that can be used to determine O-GlcNAcylation status. In order to facilitate site mapping with HCD, β-elimination followed by Michael addition with dithiothreitol (BEMAD) may be used to convert the labile O-GlcNAc modification into a more stable mass tag. For BEMAD mapping of O-GlcNAc, the sample must be treated with phosphatatase otherwise other serine/threonine post-translational modifications such as phosphorylation may be detected. Electron-transfer dissociation (ETD) is used for site mapping as ETD causes peptide backbone cleavage while leaving post-translational modifications such as O-GlcNAc intact.
In the first mechanism, Browner M.F. and colleagues proposed the base-catalysis mechanism, carried out by the conserved glutamate residue and the Zn2+ ion. In the second mechanism, the Matthews-mechanism, Kester and Matthews suggested an interaction between a water molecule and the Zn2+ ion during the acid-base catalysis. In the third mechanism, the Manzetti-mechanism, Manzetti Sergio and colleagues provided evidence that a coordination between water and zinc during catalysis was unlikely, and suggested a third mechanism wherein a histidine from the HExxHxxGxxH-motif participates in catalysis by allowing the Zn2+ ion to assume a quasi-penta coordinated state, via its dissociation from it. In this state, the Zn2+ ion is coordinated with the two oxygen atoms from the catalytic glutamic acid, the substrate's carbonyl oxygen atom, and the two histidine residues, and can polarize the glutamic acid's oxygen atom, proximate the scissile bond, and induce it to act as reversible electron donor. This forms an oxyanion transition state. At this stage, a water molecule acts on the dissociated scissile bond and completes the hydrolyzation of the substrate.
In most people with Alport syndrome (about 85%), the condition is inherited in an X-linked pattern, due to mutations in the COL4A5 gene. A condition is considered X-linked if the gene involved in the disorder is located on the X chromosome. In males, who have only one X chromosome, one altered copy of the COL4A5 gene is sufficient to cause severe Alport syndrome, explaining why most affected males eventually develop kidney failure. In females, who have two X chromosomes, a mutation in one copy of the COL4A5 gene usually results in blood in the urine, but most affected females do not develop kidney failure. Alport syndrome can also be inherited in an autosomal recessive pattern if both copies of the COL4A3 or COL4A4 gene, located on chromosome 2, have been mutated. Most often, the parents of a child with an autosomal recessive disorder are not affected but are carriers of one copy of the altered gene. Past descriptions of an autosomal dominant form are now usually categorized as other conditions. Notably, conditions associated with giant platelets and associated with mutations of MYH9 are no longer considered to be Alport variants. However apparent autosomal dominant transmission of disease associated with mutations in COL4A3 and COL4A4 does occur. Clinical utility gene card for: Alport syndrome.
Sources: en.wikipedia.org
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.
The methionine residue at the start of the chain is vulnerable to oxidation, producing a sulfoxide variant. Amide bonds can also hydrolyze, though more slowly under neutral conditions. Cold storage, oxygen exclusion and minimization of freeze-thaw cycles slow both processes but do not stop them.
A purity number on a certificate does not establish that a powder is the same product as a registered nasal medicine. Counter-ion content, residual solvents and peptide-related impurities may differ between the two. Independent verification is the only way to narrow that gap.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.